Paper34680554
Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.
Carrasco-Hernández L and 5 others. Biomedicines, 2021. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine. Papers, record 34680554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34680554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34028270 | Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. | J Med Chem | 2021 | https://conductscience.org/library/papers/34028270 | PubMed |
| 2 | 7543698 | CFTR as a cAMP-dependent regulator of sodium channels. | Science | 1995 | https://conductscience.org/library/papers/7543698 | PubMed |
| 3 | 26028628 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. | Eur Respir Rev | 2015 | https://conductscience.org/library/papers/26028628 | PubMed |
| 4 | 32554756 | CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways. | Eur Respir Rev | 2020 | https://conductscience.org/library/papers/32554756 | PubMed |
| 5 | 24040746 | Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. | Am J Respir Crit Care Med | 2013 | https://conductscience.org/library/papers/24040746 | PubMed |
| 6 | 29750581 | CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. | Expert Rev Respir Med | 2018 | https://conductscience.org/library/papers/29750581 | PubMed |
| 7 | 12396422 | Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. | J Aerosol Med | 2002 | https://conductscience.org/library/papers/12396422 | PubMed |
| 8 | 21658649 | Recommendations for the classification of diseases as CFTR-related disorders. | J Cyst Fibros | 2011 | https://conductscience.org/library/papers/21658649 | PubMed |
| 9 | 31344409 | Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. | Steroids | 2019 | https://conductscience.org/library/papers/31344409 | PubMed |
| 10 | 15463907 | High frequency of the R75Q CFTR variation in patients with chronic obstructive pulmonary disease. | J Cyst Fibros | 2004 | https://conductscience.org/library/papers/15463907 | PubMed |
| 11 | 24568560 | Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease. | Respir Res | 2014 | https://conductscience.org/library/papers/24568560 | PubMed |
| 12 | 2475911 | Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. | Science | 1989 | https://conductscience.org/library/papers/2475911 | PubMed |
| 13 | 24106801 | Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. | Am J Respir Cell Mol Biol | 2014 | https://conductscience.org/library/papers/24106801 | PubMed |
| 14 | 27561233 | Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases. | Expert Opin Drug Deliv | 2017 | https://conductscience.org/library/papers/27561233 | PubMed |
| 15 | 34379371 | Comparative Effectiveness of Roflumilast and Azithromycin for the Treatment of Chronic Obstructive Pulmonary Disease. | Chronic Obstr Pulm Dis | 2021 | https://conductscience.org/library/papers/34379371 | PubMed |
| 16 | 28006950 | Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function. | Antioxid Redox Signal | 2017 | https://conductscience.org/library/papers/28006950 | PubMed |
| 17 | 33935699 | Cystic Fibrosis Lung Disease in the Aging Population. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33935699 | PubMed |
| 18 | 25794013 | Second-hand cigarette smoke impairs bacterial phagocytosis in macrophages by modulating CFTR dependent lipid-rafts. | PLoS One | 2015 | https://conductscience.org/library/papers/25794013 | PubMed |
| 19 | 26637637 | Augmentation of CFTR maturation by S-nitrosoglutathione reductase. | Am J Physiol Lung Cell Mol Physiol | 2016 | https://conductscience.org/library/papers/26637637 | PubMed |
| 20 | 22903797 | Reactive oxygen species: from health to disease. | Swiss Med Wkly | 2012 | https://conductscience.org/library/papers/22903797 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41055920 | Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR. | Sci Prog | 2025 | https://conductscience.org/library/papers/41055920 | PubMed |
| 38377145 | Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF). | PLoS One | 2024 | https://conductscience.org/library/papers/38377145 | PubMed |
| 37437299 | Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full. | Am J Respir Crit Care Med | 2023 | https://conductscience.org/library/papers/37437299 | PubMed |
| 37250046 | Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks. | Front Microbiol | 2023 | https://conductscience.org/library/papers/37250046 | PubMed |
| 36768629 | The COPD-Associated Polymorphism Impairs the CFTR Function to Suppress Excessive IL-8 Production upon Environmental Pathogen Exposure. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768629 | PubMed |
| 35203708 | Chronic Obstructive Pulmonary Disease: The Present and Future. | Biomedicines | 2022 | https://conductscience.org/library/papers/35203708 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADH5 | 128 | PubTator's text mining | https://conductscience.org/library/genes/128 | NCBI Gene |
| CAT | 847 | PubTator's text mining | https://conductscience.org/library/genes/847 | NCBI Gene |
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 | NCBI Gene |
| FGB | 2244 | PubTator's text mining | https://conductscience.org/library/genes/2244 | NCBI Gene |
| PDE4A | 5141 | PubTator's text mining | https://conductscience.org/library/genes/5141 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34680554
GET https://conductscience.org/api/papers/v1/34680554/references?page=2